How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

“Where the cancer is involving both sides of the prostate and is intermediate or high risk, then surgery is highly ...

MRI visibility and the presence of secondary Gleason pattern 4 at baseline are associated with progression to treatment and ...

One area many men are reluctant to visit doctors about is their prostate health. Often driven by embarrassment, ...

Patients with metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to ...

Investigators created a prognostic digital pathology-based AI score to identify a subset of patients with clinically high-risk prostate cancer more likely to benefit from the addition of abiraterone ...

With a team of dedicated specialists, the New Mexico Cancer Center uses the latest technology, from blood tests and imaging ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Johnson & Johnson JNJ announced positive top-line data from a late-stage study evaluating the combination of niraparib, a ...

Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive ...

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Notably, the ARCHES trial had the longest median follow-up among ARPI trials at 61.4 months. During this period, median overall survival was not reached in either treatment arm. At 5 years, 66% (two ...